Even with combination chemotherapy, historic series show 5-year progression- or failure-free survival rates between 20% and 30% for nodal-based diseases (with the exception of anaplastic lymphoma kinase [ALK]-positive ALCL in young patients, which tends to have more favorable outcomes) [4,5,6]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.